Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3561676 | 1.00 | USP2 (0.42) | USP2SMN1; SMN2NR1H2MAPK1MAPT | |
| SCHEMBL18129961 | 1.00 | USP2 (0.42) | USP2SMN1; SMN2NR1H2MAPK1MAPT | |
| SCHEMBL27567585 | 0.87 | USP2 (0.45) | USP2SMN1; SMN2NR1H2MAPK1MAPT | |
| SCHEMBL14959559 | 0.86 | HPGD (0.44) | USP2SMN1; SMN2NR1H2MAPK1MAPT | |
| SCHEMBL14452943 | 0.86 | HPGD (0.44) | USP2SMN1; SMN2NR1H2MAPK1MAPT | |
| SCHEMBL1184732 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2NR1H2MAPK1MAPT | |
| SCHEMBL2392691 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2NR1H2MAPK1MAPT | |
| SCHEMBL796400 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2NR1H2MAPK1MAPT | |
| SCHEMBL193100 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2NR1H2MAPK1MAPT | |
| SCHEMBL30289051 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2NR1H2MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012123312-A1 | PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | WO | disclosed |
| US-7365077-B2 | Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-04-29 | — | — | US | disclosed |
| US-20060252769-A1 | Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor | SMTIHKLINE BEECHAM P.L.C. (GB) | 2006-11-09 | — | — | US | disclosed |
| WO-2003051873-A1 | PIPERAZINE COMPOUNDS AND THEIR PHAMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252769-A1 | Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor | HCRTR2, HCRTR1, NPSR1 | USP2 2478/4885SMN1; SMN2 3631/4885NR1H2 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.